Answers are grounded in this paper and cite their sources.
Background: Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are the leading causes of end-stage kidney disease (ESKD) globally. Although renin-angiotensin system (RAS) inhibitors (ACE inhibitors or ARBs) represent standard therapy, substantial residual renal risk persists. This meta-analysis evaluated whether adding sodium-glucose cotransporter-2 (SGLT2) inhibitors to RAS blockade reduces ESKD progression compared to RAS monotherapy in adults with T2DM and/or CKD. Methods: We searched PubMed up to November 2026 and screened reference lists of prior reviews for randomized controlled trials (RCTs) and cohort studies comparing combined SGLT2 and RAS inhibition against RAS monotherapy in adults with T2DM and/or CKD. The primary outcome was ESKD incidence. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects inverse-variance model. Results: Three large-scale studies comprising 121,455 patients (7,531 receiving combination therapy and 113,924 receiving RAS monotherapy) met eligibility criteria. Combined SGLT2 and RAS inhibition significantly reduced ESKD risk by 35% compared to RAS monotherapy (pooled HR: 0.65; 95% CI: 0.55–0.77; P < 0.0001). No statistical heterogeneity was observed across the studies (I² = 0.0%, P = 0.7875). Conclusion: Adding SGLT2 inhibitors to standard RAS blockade significantly lowers the risk of ESKD progression in adults with T2DM and/or CKD, supporting early dual therapy for optimal renoprotection.
No takes yet. Share an insight, caveat, or question.
Yousef Ismail Ibrahim Jbor (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: